TORRANCE, Calif., October 6, 2015 – Emmaus Life Sciences, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, announced that management will present an abstract from its completed FDA phase 3 sickle cell disease (SCD) trial at the 9th Annual Sickle Cell and Thalassaemia Advanced Conference. The conference takes place October 7-9, 2015 at The Hilton - London Tower Bridge in London.
The sickle cell and thalassaemia conference is a forum for dialogue and interaction between the leading world experts in sickle cell disease and thalassaemia and health care professionals at the frontline of care, and is intended to update those working with patients across the world with SCD to consider efficient and safe ways to manage patients.
“There is great need for a widely available and well tolerated treatment for the sickle cell disease patients in Europe,” said Yutaka Niihara, M.D., MPH, Chairman of Emmaus. “As the only company to complete a phase 3 trial in the U.S. in nearly 20 years, we look forward to sharing the clinical trial results with the sickle cell disease community in Europe.”
Emmaus’ SCD therapy has Orphan Drug designation in the U.S. and Europe and Fast Track designation from the FDA.
About Emmaus Life Sciences
Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.
For more information, please visit www.emmauslifesciences.com.
Contacts:
Media:
Lori Teranishi for Emmaus Life Sciences, Inc.
510-290-6160
lteranishi@iq360inc.com
Investors:
Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
msheldon@pondel.com